Afya, the largest medical-education group in Brazil by MEC-approved seats, arrived at its first quarter of 2026 carrying two stories at once. The undergraduate medical school engine - the fortress that built the company - is finishing its high-growth chapter: operating seats climbed 6.4% to 3,768, yet the ceiling on new authorizations is the defining constraint, and the quarter's revenue growth slowed to single digits. At the same time, the company is pushing the next act, a physician-centric digital ecosystem spanning continuing education and medical-practice software, where it is spending deliberately and margin is absorbing the cost.
The central tension is what the quarter makes concrete: revenue grew 8.2% year over year to R$1,012.7 million (US$184 million), still solid, but adjusted EBITDA rose only 4.0%, pulling the adjusted EBITDA margin down 200 basis points to 50.5% as continuing education and medical practice solutions burned through investment. Net income managed just 1.8% growth, additionally hit by a Pillar Two global-minimum-tax charge. The undergraduate engine remains staggeringly profitable - the medical school alone carries a net ticket up 4.6% and 100% occupancy - but it is growing at a pacesetter closer to the Brazilian economy than to the double-digit compounder investors once paid for.
What changed, and why it matters: the stock trades near the bottom of its 52-week range at roughly $13.58, about nine times trailing earnings, while its global education peers sit at fourteen to seventeen times. That discount is the market pricing either a moat in permanent maturation or a Brazil-specific risk premium that has not receded. The thesis hinges on whether the two nascent segments - continuing education up 11% and medical practice solutions up 4.2%, each growing their paying bases - can graduate into the growth engine that the seat-constrained undergraduate business no longer can. The next quarterly report is the first read on whether that transition is advancing or stalling.